Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	HK$23.44	+4.64%	101,300
19/08/26	HK$22.40	-3.78%	106,200
18/08/26	HK$23.28	+5.72%	102,800
17/08/26	HK$22.02	+1.76%	106,000
14/08/26	HK$21.64	+0.93%	102,000

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

20.10CNY

Average target price

23.26CNY

Spread / Average Target

+15.70%

Consensus

Net sales - Rate of surprise

Company calendar

Delayed Hong Kong S.E. 11:09:09 20/08/2026 +03			5-day change	1st Jan Change
23.44 ^HKD	+4.64%		+9.33%	-23.10%

07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI

Market Cap	2.85B 3.32B 424M 363M 339M 311M 584M 40.55B 595M 4.02B 1.57B 20.32B 1.59B 1.56B 67.28B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.16B 2.52B 321M 275M 256M 235M 442M 30.69B 450M 3.04B 1.18B 15.38B 1.2B 1.18B 50.92B	EV / Sales 2026 *	3.39x	EV / Sales 2027 *	2.54x
Free-Float	28.85%	Yield 2026 *	-	Yield 2027 *	-

07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
07-31	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
06-30	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-31	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
02-26	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
02-26	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI
02-06	Medtide Gets CSRC Nod for Hong Kong Share Full Circulation	MT
12-30	2,565,000 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-DEC-2025.	CI

1 day	+4.64%
1 week	+9.33%
Current month	+4.09%
1 month	+0.60%
3 months	+7.13%
6 months	-10.53%
Current year	-23.10%

Medtide Inc. Stock

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news : Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Medtide Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 week	21.02	24.5
1 month	19.8	24.5
Current year	19	30.46
1 year	19	41.54
3 years	19	41.72
5 years	19	41.72
10 years	19	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	11/06/2020
Wei Qun Xu DFI	Director of Finance/CFO	53	01/10/2020
Li Jun Ding DFI	Director of Finance/CFO	50	31/07/2026

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	11/06/2020
Xiang Li Li BRD	Director/Board Member	51	27/01/2022
Xiang Li BRD	Director/Board Member	63	27/01/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+4.64%	+9.33%	-36.41%	-	405M
LONZA GROUP AG	+1.14%	+2.27%	+2.38%	+24.14%	50.5B
REVOLUTION MEDICINES, INC.	-1.36%	+4.82%	+485.55%	+614.84%	46.01B
BEONE MEDICINES AG	-2.04%	+3.69%	+19.34%	+91.23%	42.85B
IQVIA HOLDINGS INC.	+2.72%	+6.02%	+33.33%	+19.66%	41.03B
CELLTRION, INC.	0.00%	-3.91%	+18.49%	+47.98%	32.02B
MEDPACE HOLDINGS, INC.	+0.72%	+5.27%	+31.55%	+145.37%	16.98B
ASCENDIS PHARMA A/S	-1.85%	+3.48%	-	-	17.05B
EUROFINS SCIENTIFIC SE	+3.06%	+3.88%	+5.81%	+35.00%	14.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+3.62%	+82.64%	+46.53%	13.84B
Average	+0.75%	+3.05%	+71.41%	+128.09%	27.5B
Weighted average by Cap.	+0.19%	+2.75%	+104.66%	+152.88%

	2026 *	2027 *
Net sales	636M 741M 94.51M 80.92M 75.5M 69.27M 130M 9.04B 133M 896M 349M 4.53B 355M 347M 15B	807M 941M 120M 103M 95.88M 87.98M 165M 11.48B 169M 1.14B 443M 5.76B 451M 441M 19.05B
Net income	-	-
Net Debt	-693M -808M -103M -88.26M -82.35M -75.56M -142M -9.86B -145M -977M -381M -4.94B -387M -379M -16.36B	-802M -936M -119M -102M -95.31M -87.45M -164M -11.42B -168M -1.13B -441M -5.72B -448M -438M -18.94B